About Us

Serentis is a privately owned biopharmaceutical company founded in 2006 with the objective of developing a pipeline of innovative proprietary products to address unmet medical needs.

Serentis Management Team (from left to right): Dr Alan Rothaul, Peter Keen, Dr Robert Tansley, Tim Sharpington, Dr Andy Baxter and Gunnar Staaf

Our strategy is to establish a clinical stage development pipeline and to move rapidly to proof-of-principle.  The current pipeline has been sourced both through our in-house, low-risk discovery function and through licensing and acquisition of external assets.  Products are selected based on the potential competitive advantage and the commercial opportunity they provide.

The management team includes professionals with many years of pharmaceutical and biotech experience and a strong track record of delivering fast, efficient development programmes with clear commercial positioning.

With significant financial backing from leading venture capitalists, Serentis has, in a short period of time, been able to develop products which promise to address unmet medical needs for patients.  Please do not hesitate to contact us if you need further information. 

Tim Sharpington, Chief Executive Officer.